Taltobulin
| Title | Journal |
|---|---|
| Mitochondrial dysfunction confers resistance to multiple drugs in Caenorhabditis elegans. | Molecular biology of the cell 20100315 |
| Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. | Bioorganic & medicinal chemistry letters 20100301 |
| Total synthesis and biological evaluation of tubulysin U, tubulysin V, and their analogues. | Journal of medicinal chemistry 20090122 |
| Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. | International journal of cancer 20080515 |
| Tubulysin analogs incorporating desmethyl and dimethyl tubuphenylalanine derivatives. | Bioorganic & medicinal chemistry letters 20080501 |
| Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. | World journal of gastroenterology 20061114 |
| Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin. | Biochemistry 20050510 |
| Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. | Biochemistry 20041109 |
| Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. | Molecular cancer therapeutics 20041001 |
| Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286). | Journal of medicinal chemistry 20040909 |
| Probing the interaction of HTI-286 with tubulin using a stilbene analogue. | Journal of the American Chemical Society 20040818 |
| D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors. | Bioorganic & medicinal chemistry letters 20040816 |
| Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. | Cancer biology & therapy 20040301 |
| Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules. | Biochemistry 20031125 |
| HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. | Cancer research 20030415 |